In 2014, the pharmaceutical industry in both China and the United States contributed more corporate profits than the semiconductor industry, and with a record population of 1.4 billion, the pharmaceutical and medical industry is destined to be one of the largest industries in the country. Pen, fun, pavilion www. biquge。 info

The United States is the center of global medical research.

On the list of the top 50 global pharmaceutical companies, the United States accounts for just half, the United Kingdom, Switzerland, and France have 2 each, Germany has 4, Japan has 7, and China has 3 - Huateng Medical Technology Group Corporation, Federal Pharmaceutical Group, and China United Pharmaceutical Group Corporation.

Huateng Medical is a truly international pharmaceutical company, with R&D centers in 14 countries and 5 patented prescription drugs with sales of more than US$1 billion worldwide;

Federated Pharmaceutical is China's largest generic drug giant and over-the-counter drug supplier, which is the first pharmaceutical company in China jointly controlled by the Huayin Consortium and state-owned capital.

China United Pharmaceutical Group Corporation is a state-owned pharmaceutical giant established in 2012, and its products are mainly from Sino-foreign joint venture pharmaceutical companies, and it is currently the largest supplier of general medicine in China.

In China, the fourth largest pharmaceutical company is China Pharmaceutical Bureau Group, which owns Jiuzhitang, Huqingyutang, Tongjitang, Nianci'an, Jianmin, Dong'e, Sanjiu, Jiangzhong Pharmaceutical, Taiji, Renhe, Ma Yinglong and other leading Chinese patent medicine enterprises.

These are the four leading enterprises in China's pharmaceutical industry, which just represent the four major sectors of patented drugs, generic drugs, general medicines, and Chinese patent medicines.

In addition to the four giants of Huateng Medical, Federal, Zoomlion and China Pharmaceutical Bureau, Huayin Consortium holds a certain proportion of shares in more than 30 listed pharmaceutical companies in China, providing financing and consulting services, promoting scientific research and innovation, and optimizing management and product structure.

Xu Teng told the truth, in order to support the development of China's pharmaceutical industry, he has done everything he can.

However, the overall environment of the domestic pharmaceutical industry is indeed distorted.

The gap between China and the United States in this area is quite exaggerated...... According to Xu Teng's assessment, this is the industry with the largest gap between China and the United States.

All pharmaceutical giants in the world rely on the medical insurance and welfare systems of Europe and the United States, and the vast majority of the prices of patented prescription drugs are difficult for ordinary wage earners to support on their own income.

It is a fact that China is, after all, a developing country.

Most of the retired elderly in China have a pension of just over 2,000 yuan per month, but in the international market, which box of patented drugs does not start at 2,000 yuan? Gleevec, which treats myeloid and acid phagocytes, acute lymphoblastic leukemia and gastrointestinal cancer, has a box of 23,000 yuan per month.

Xu Teng said responsibly that in countries with a per capita annual income of less than 30,000 US dollars, most people cannot afford to eat patented drugs.

At the same time, China's pharmaceutical industry is very lacking in scientific research, talents, theory, experience, and funds, and the gap between it and the international advanced level is at least 20 years, coupled with the lack and imperfection of relevant laws and regulations, as well as the reality of low per capita income and pharmaceutical consumption capacity in Chinese...... As a result, there is a huge gap between China and the United States in the field of patented drug research.

Xu Teng is not without efforts, it is really more difficult than the semiconductor industry, so after 2009, he can only be a person who knows the times and shifts his energy to the field of generic drugs.

Behind the scenes, he promoted the establishment of "Federal Pharmaceutical" and the state-owned "China United Pharmaceutical Group", aiming at generic drugs, and fought against various interests in the domestic medical and pharmaceutical industry for five years.

So far, the results have been mediocre.

The entire Chinese medical and pharmaceutical industry is chaotic, dancing wildly, and extremely distorted.

China United Pharmaceutical Group, a giant of central enterprises, was helpless to retreat, retreat to engage in general medicine, and like other pharmaceutical companies, engage in the construction of a "marketing representative system".

Xu Teng's energy is also limited, he also has to eat, he also has to support his own scientific research team, and he also has to support the employees of Bo'an Hospital and Pharmaceutical Factory, it is impossible to offend all aspects of the domestic pharmaceutical industry several times!

Of course, he has its own system, from community hospitals to tertiary hospitals, Boan Group, a subsidiary of the Huayin Consortium, has a complete set of medical systems, covering the whole country, which is definitely a little better than the central enterprise giants.

What is the source of all the problems?

The first is the idea of "how fast and how much is better" in the previous medical reforms; the second is to completely ignore the reality of low income and low welfare in developing countries, and blindly integrate with international standards.

Can this not be distorted?

Xu Teng and the entire Boan Group's senior management attitude is the same, the more this market distortion stage, the more good opportunities to establish word-of-mouth, brand and system, every year non-stop huge amount of capital injection, robbery doctors, customers, build a system, build a reputation.

In the long run, as China's aging population increases, the industry is a sure win.

There are now 600,000 medical students graduating every year in the country, and at least 4/5 of the graduates actually change careers, so there is no problem with the supply of talents.

In the past seven years, Boan Group has not only gradually recruited senior doctors from public hospitals, but also gradually increased the number of medical graduates recruited every year, and in 2013, it recruited a record-breaking 120,000 people, with master's and doctoral students accounting for one-third.

Xu Teng didn't hit this distorted market head-on, he just used his strength to do things silently, not to speak, not to shout, and not to be high-profile.

He injects 70 billion yuan through the consortium every year, Boan Group raises 70 billion yuan itself, absorbs 70 billion domestic private equity, insurance and other social capital, and expands the basic market by means of joint stock operation, contract management and franchise operation, from 2005 to 2014.

Prior to 2005, Boan Group was already the largest private hospital chain in the country, and through the acquisition of AHS Medical, the third largest for-profit hospital chain in the United States, it became the world's largest for-profit medical chain.

Xu Teng is still silent, only investing, not speaking, and waiting until he accounts for half of the Chinese medical market, and then speaks with strength.

Generally speaking, the price of prescription drugs in the entire Boan medical system is 20% lower than that of public hospitals, and there is no problem with a 30% reduction, but this cannot be done, and it will also have an impact on its own profits and expansion rate.

Boan Group is also a multi-brand operation, in addition to the "Bo'an" series of second- and third-class general hospitals, community hospitals, nursing homes, as well as Bo'ai ophthalmology, maternity and infant and beauty hospitals, as well as high-end Anren Medical Center and Annes Medical brand differentiated operation in China, its national chain pharmacy brands have 4, and regional chain pharmacies have more than 15.

In 2014, there were 13,314 public hospitals, 14,752 private hospitals, 1097335 primary and community medical institutions in China, 7,560 private hospitals, 733 tertiary hospitals, 4,297 secondary hospitals in China's primary community medical institutions, including a total of 270,000 authorized franchises.

If the domestic medical and pharmaceutical market is not so distorted, there is no room for the rapid development of Boan Group.

So, distortion is a good thing.

At this stage in 2014, it is like the darkness before dawn for Xu Teng, he is a master of balancing the interests of all parties, but how to balance the interests of the domestic medical and pharmaceutical systems and overseas pharmaceutical giants, even if he keeps cutting, the reason is still messy!

Xu Teng went to the United States this time, in fact, he had a new idea, to use the Huayin Consortium's right to speak in the domestic pharmaceutical industry, to engage in a new idea - authorized drugs, to license your patented drugs to me for local production, most of the profits to you, but to push the price to the range that domestic patients can accept.

Because imported drugs are generally not included in domestic medical insurance.

The authorization of foreign companies to produce is itself to avoid a lot of troubles in the domestic application for compulsory generic and generic drug approval, and can also enjoy the benefits of medical insurance coverage and expand sales.

This kind of "authorized drug" is a very Chinese approach, which avoids import tariffs and layers of marketing agents, and allows the Boan medical system to provide patients with patented drugs at lower prices, and can enjoy medical insurance reimbursement.

Xu Teng did not need to directly intervene in the negotiations, Huateng Medical, Federal Pharmaceutical, and Zhonglian Pharmaceutical all sent teams to negotiate with various pharmaceutical giants in the United States, and he only met with the chairmen of some pharmaceutical giants alone to persuade each other to participate in this cooperation.

Now the biggest obstacle is the domestic medical and pharmaceutical system, claiming that this "authorized drug" will greatly increase the burden of the domestic medical insurance system, in the final analysis, it is worried that patients will turn to the Bo'an hospital system in a large area, and a competent unit is also considering formulating new rules and regulations to "manage a tube".

All this, Xu Teng didn't want to scold his mother, he spoke with strength.

Now for Boan Group, for Xu Teng, it is a pre-dawn darkness, which has the ability to change China's medical and pharmaceutical industry, but there is still a little thing missing, and there is still a little bit of gap.

Just like Xu Teng's current situation in the United States, it is very dark and dangerous, but just a little, he can tear through the darkness and turn the whole situation around.

The last week of November.

Xu Teng sent his wife Xia Li and several children to the airport and asked them to go back to Jiangzhou, of course the children were not happy, they had just made friends at Dalton Private School, and they were going back to Jiangzhou again.

It's annoying!

Fortunately, they are still young, and they are even more worried about leaving their father for the time being, leaving this bustling and beautiful New York.

Xia Li didn't have anything to say, she could roughly guess that Xu Teng would definitely have to do something again, if it weren't for the complicated situation, he wouldn't change his plan to let the children study on an exchange at Dalton School for a year.

She didn't ask much, just asked Xu Teng to take care of herself.

Xu Teng nodded silently and calmly, and watched Xia Li lead the children to board the plane, take the Führer-class A340 of the Huayin Consortium, and leave the sky of New York.

The time for the decisive battle has arrived.

In the past two weeks, the Huayin AIG consortium and the Big Five of Wall Street have controlled the market behind the scenes, cutting the exchange rate of the Brazilian real and the stock market in half, which has fallen for half a year, and has been cut in half.

One can imagine how dire Brazil's current economic and financial situation is.

Brazil has been taught a lesson by Wall Street for so many years, and it has long been learned to be obedient, only to protect foreign exchange, not to protect the exchange rate, you want to kill or chop, whatever.

That's right.

Xu Teng and Wall Street just want to slash the foreign exchange market, stir up public anger, provide a reason for the corrupt legislators to impeach the president, and behead the only left-wing president in Brazilian politics who cares about the country and the nation, and is not corrupt.

The impeachment has already begun, and it is estimated that it will take two months before there is a result.

The Brazilian Iron Lady knew very well that as soon as she stepped down, these members of Congress would soon sell off Petrobras, Vale and Brazil's power grid to pay off their debts, and would rather be impeached than go to jail.

It's tragic, isn't it?

Xu Teng will not shed a single tear for her, because this is the bloody evil of capitalism, international capitalists, just to enslave and colonize the world in a freer, more human rights, and more democratic way.

There is nothing wrong with freedom, human rights, and democracy, which are universal values, but what is wrong is that if there are classes in the world, and if there is a gap between the rich and the poor, they will definitely be exploited.

As the saying goes, ideals are beautiful, but reality is cruel.

From theory to reality, in fact, it is just a different way to enslave the world.

On the way out of the airport by car.

Xu Teng received an email from Mr. Cinton, and the former president had heard through his own channels that Abbott shareholders wanted to sell Abbott, which was very interesting news.

In other news, Pfizer is preparing to raise its offer for Allergan, either to acquire AstraZeneca, to move its headquarters to the United Kingdom, or to Ireland, or to buy the Irish pharmaceutical company Shire, which is controlled by the British Phoenix Capital Group.

Allergan is nominally an American company, but its actual headquarters was relocated to Ireland as early as 2009 with the assistance of the Huayin AIG consortium.

Pfizer actually wanted to run for a long time, but every time it was stuck by the White House and was not allowed to run.

The current corporate tax in the United States is 35%, and Pfizer has long wanted to die, and will not hesitate to acquire Allergan at a high price, or spend $70 billion to acquire AstraZeneca, or buy Shire Pharmaceuticals.

Xu Teng took a general look and was sure that this was passed on to Mr. Cinton by Pfizer and Abbott through the channel of the Cinton Foundation, and then to Xu Teng.

In 2013, Abbott Group was spun off into two companies, Abbott, which holds traditional generic drugs and various expired patented drugs, as well as Abbott Nutrition and Maternal and Infant Industries, and AbbVie, which owns all of Abbott's patented drugs and the scientific research team of the entire Abbott Pharmacy Division.

Don't look at the Abbott Group still has a market value of 70 billion US dollars, in fact, no one really wants it, the shareholders behind the scenes have already moved their core assets to AbbVie, and AbbVie has only been listed for two years, even in the current global economic crisis, the market value is still as high as 90 billion US dollars.

As for Pfizer, the goal is obvious, it wants to escape from the United States through the power of the Huayin AIG consortium, yes, the tax is too high.

For such a big thing, it is estimated that Goldman Sachs and AIG will have to join forces to get the White House to let it go...... I don't think it can be done yet.

Xu Teng roughly thought about it, weighed the pros and cons, and quickly wrote back to Mr. Cinton, proposing a new plan that is most likely to pass the White House review - AstraZeneca's acquisition of Pfizer, and Ireland's Charles Pharmaceuticals acquisition of Abbott.

There is no doubt that neither AstraZeneca nor Shire Pharmaceuticals have such strength, but the fact that the controlling party behind both companies is The-ShunFamliy, which means that a miracle is possible.

"Obviously, these are the two best options, and for Boston Life, it's the best outcome, and Pfizer is out of the race to acquire Allergan, which is the most advantageous win-win-win option. If we can agree, there is no problem, and even if there is a problem, we can solve it. Mr. Cinton's point was clear, and the Cinton family was responsible for betraying the country on the condition that the The-Shun family persuade AIG to lead the other half of Wall Street in support of the Democratic Party and his wife's presidential candidacy.

!

Xu Teng had nothing to say.

If you want to say which one is stronger, New York, USA, is looking for the Cinton family!

To put it bluntly, these two mergers and acquisitions are because American capital wants to avoid the huge corporate tax in the United States and flee to the two tax havens of Ireland and the United Kingdom, and the corporate tax rate of the high-tech industry in the United Kingdom is also very low, as long as the investment in scientific research in the United Kingdom reaches a certain percentage, the actual tax rate is similar to that of Ireland.

This presidential election, the more you elect, the more miserable it becomes!

On the other hand, whether Pfizer is a good company or not is itself a good company is also a matter of opinion, objectively speaking, it is not.

With the exception of Viagra, Pfizer has had little success in launching a patent with sales of more than $1 billion in sales over the past 15 years, and has relied on acquisitions to sustain growth, having suffered from a serious takeover since its $90 billion share swap acquisition of Warner Lambert in February 2000.

In 2002, Pfizer invested $60 billion to acquire Pharmacia, in 2006 it acquired PowderMed, from 2007 to 2008 it acquired seven biopharmaceutical companies including BioRexis and CovX, and in 2009 it invested $68 billion to acquire Wyeth.

In Xu Teng's view, Pfizer's large-scale acquisitions in the past 15 years have basically only purely supported market value and stock price, which is the typical price of a lack of major shareholders and complete control of a company by so-called professional managers, and will do whatever it takes to maintain a short-term market value.

Because listed companies in the United States can maintain market value in order to stabilize the position of chairman and CEO, and only then can they have high profit dividends and bonuses, which is the motivation of professional managers.

In contrast, AstraZeneca, which transformed into a family business in 2008, has not made large-scale mergers and acquisitions, but has provided more support and dividend agreements to its scientific research team, supporting the company's transformation from a traditional chemical pharmaceutical giant to a biopharmaceutical giant.

By 2013, AstraZeneca's biopharmaceutical business had sales similar to those of the traditional chemical pharmaceutical business, with 14 prescription patented drugs with annual sales of more than US$1 billion.

In terms of total sales, AstraZeneca Group can only rank seventh in the top 50 global pharmaceutical companies, and its net profit and market value are fifth.

In terms of debt ratio, Pfizer has reached 30% of the total market value after large-scale mergers over the years, and to a certain extent, Pfizer is a negative equity company.

Pfizer has $44 billion in annual prescription drug sales, 1/3 of patented drugs, less than $9 billion net profit after tax, and $42 billion in debt.

From this point of view, according to the current market value of Pfizer Group of 193 billion US dollars, it is foolish for Xu Teng to invest 193 billion US dollars to buy Pfizer Group.

Although Xu Teng proposed such a deal plan to Mr. Cinton, he still did not dare to start negotiations easily.

After thinking about it for a while, he wrote a longer reply to Mr. Cinton, not rushing to make a decision for the time being, because the deal was complicated.

The capital market has never been cheap and no good goods, but the enterprises that are willing to transfer are not good goods.

This is the biggest risk between mergers and acquisitions, because the companies that you can buy in the capital market must have problems in the first place. Pfizer's financial risk and high debt, Abbott's high-quality asset divestiture, leaving only an empty shell and sunset assets, these are all tricky questions.

In contrast, don't look at the pharmaceutical industry investments under The-ShunFamliy and the Huayin AIG consortium, in addition to AstraZeneca, there is a lack of international giant-level pharmaceutical companies, and its four major emerging pharmaceutical companies in the "United States" Alexion, Baxalta, Celgene, and Regeneron are all small and strong in the field of biopharmaceuticals, and they basically specialize in the industry, each with several very strong professional fields, and they are small and fine.

Huateng Medicine is larger, focusing on chronic diseases of the three highs, chronic diseases of the liver and kidney, immune system diseases, targeted drugs for cancer and vaccines for children.

Over the years.

Xu Teng's plan for the pharmaceutical industry is very clear, focusing on the development of the two giants of AstraZeneca and Huateng Medical, and the merger of French Servier + Belgian USB to form the third giant...... The merger was recently approved in the European Union, and the French corporate tax is getting higher and higher, and the Belgian corporate tax is much lower, and the two sides can save more than a billion euros a year in corporate tax alone by moving their headquarters to Belgium.

Alexion, Baxalta, Celgene, and Regeneron focus on small but fine routes.

China's unique field of proprietary Chinese medicine is the China Pharmaceutical Bureau Group.

This 3+4+1 lineup can spread risks to the greatest extent and achieve full coverage of the entire pharmaceutical industry.

In the field of generic drugs, Federal Pharmaceutical, a subsidiary of the Huayin AIG consortium, Perrigo of Canada, and Shire of Ireland, a subsidiary of Phoenix Capital, each of which researches generic drugs separately, and has scientific research and production bases in the three major markets of China, the United States and Europe.

IIIumina is in the field of testing technology and laboratory equipment development, and Boston Life and TCL Medical Technology are in the field of medical devices.

This is Xu Teng's investment in the pharmaceutical industry from 2004 to 2009 to gradually improve the industrial chain and layout planning.

Perfect!

It's perfect, Xu Teng feels that his IQ is too high.

In 2009, when he provided financing for Pfizer to acquire Wyeth, he also took the opportunity to buy Wyeth's nutritional pharmacy and maternal and infant dairy businesses, as well as some generic drug businesses, which was even more perfect.

There's a temptation!

On the one hand, Pfizer's dangerous financial risks and huge debts are on the other, and on the other hand, Pfizer's annual prescription drug sales revenue is as high as $44 billion.

Sure enough, people who are in a hurry to sell their businesses must act faster.

As soon as Xu Teng returned to his office on the 75th floor of the Chrysler Building, Yin Ruide, chairman and global executive president of Pfizer Group, had arrived in a hurry, and without making an appointment in advance, he ran over to visit Xu Teng and was in a hurry to negotiate this big deal.

After all, it is the world's No. 1 pharmaceutical giant with a market capitalization of $193 billion.

Xu Teng still met each other, and when they talked about it, both of them were surprised, Yin Ruide's real idea was actually to merge Huateng Medical, which was very beautiful, how much money did Xu Teng invest in Huateng Medical to save 5 patented drugs with global sales of more than $1 billion?

What's more, Huateng Medical is a dominant company in the domestic biological vaccine market, and the global scientific research system is perfect, and the past few years are the peak period of achievements!

Pfizer Group's debt ratio is as high as 30%, which can be called the world's most debt-ridden pharmaceutical giant, where can it afford to invest $35 billion to acquire Huateng Medical Technology Group Co., Ltd., Yin Ruide's idea is a share swap agreement.

It's a beautiful bubbling.

"Who did you hear that I was going to sell my pharmaceutical company?" Xu Teng was not very polite, and directly put the teacup on the table, he didn't know how Mr. Cinton passed the news in the middle, and he really had the ability to pass it like this.

With Xu Teng's understanding of Cinton, the former president, it is impossible to talk nonsense or spread wrong news, after all, he is the most famous of the four former presidents of the United States who are currently alive.

There is only one answer.

Yin Ruide thought too much about himself.

"I'm sorry, but I just heard from a friend that you were willing to make a deal to help Pfizer move its headquarters to the UK, and that our mutual friend was willing to go to the White House to mediate and help us achieve our goal. Yin Ruide said truthfully and bluntly, if he is not mistaken, Huateng Medical Technology Company is registered in the Cayman Islands.

He was not mistaken, but this was only to facilitate Huateng Medical Technology's overseas mergers with other companies, as well as to facilitate its listing and audit on the NASDAQ, and its domestic business was mainly based on the Jiangzhou High-tech Park.

"My condition is that AstraZeneca will buy Pfizer, you can make an offer, we can talk, and if the two sides can reach a preliminary agreement, the two companies will continue to talk about the details. Xu Teng was even more convinced that Yin Ruide was pretending, that is, he deliberately gave it a try, and if he succeeded, he would make a lot of money.

In business, it's all the same, and everyone wants to pick up cheap.

Stock market investment also has a certain superstitious psychology, Pfizer Group is actually not worth 1930 at present, and many investment institutions just blindly believe that this company can restore the glory of the viagra era.

On the other hand, the United States is now mainly semiconductor technology stocks, network technology stocks and biotechnology stocks supporting the market, as the world's largest pharmaceutical company by market capitalization, Pfizer Group's price-earnings ratio is higher than Huateng Medical, which is also normal.

Xu Teng's investment in this industry is very large, the investment time is very long, he is telling the truth, Huateng Medicine is underestimated, Pfizer Group is overestimated.

are also industry insiders, how can Yin Ruide not know, like a dream, he wants to try to buy Huateng Medical and eliminate a competitor!

At this moment, Xu Teng's evaluation of this person was lowered to a lower level, and it was described in four words, ghostly.

Pfizer Group has today's situation, this person is actually "the greatest contribution", this person has been the chairman of the board for 17 years, just in time to catch up with the success of Viagra, did not use huge profits to expand the company's technology departments in the field of biopharmaceuticals and genetics, blindly relying on mergers and acquisitions to expand the market value and scale of operations, the result is today's situation.

"Pfizer is the pharmaceutical giant with the world's largest prescription drug sales, we have excellent corporate value and competitiveness, and we ...... in the world!" Yin Ruide raised his hands and promoted the greatness of Pfizer Group to Xu Teng with great interest, but he did not finish his words.

"Don't talk this nonsense to me, you have 35% corporate taxes, $42 billion in debt, $4 billion in taxes and $3 billion in interest to pay every year. Among the top 50 global pharmaceutical companies, except for you, no company has a debt ratio of more than 30%, and you actually tell me about competitiveness?" Xu Teng directly interrupted the other party's nonsense, if his co-partner would run Pfizer's dead virtue, he would have let the other party get out of the game.

"Viagra's patent rights are about to expire this year, and Lipitor will expire in 2011, and there should be a large number of generic drugs on the market in the next few years, and the patent rights of the antibiotic Zyvox, the anti-cancer drug Sutent, Enbrel and the biological vaccine Peier will also expire in these two years. Pfizer has less than 10 of the 110 patented drugs in the world with sales of more than $1 billion, and it will decrease to 6 in 2017, and when you buy Warner Lambert, your standard return on equity is 43%, when you buy Wyeth, the standard return is 22%, and last year, your standard return was 15%. ”

"You actually tell me about competitiveness?" Xu Teng pointed to his head and clearly told the other party, "I can remember the financial report data of all the world's top 500 companies in the past five years, which company has competitiveness, I may have more say than you!"

Yin Ruide's face was silent with a blue face, he was trying his luck to see if he could buy Huateng Medical, not to accept humiliation.

In any case, he is also a top American CEO in his sixties, a tycoon in the global pharmaceutical industry, and a world-renowned pharmaceutical company who personally cultivated Pfizer from the world's top 10 pharmaceutical company to the world's largest pharmaceutical company.

"Give me an offer and let me see if we don't have to continue talking yet. Xu Teng actually doesn't like to offend these corporate giants with real power, let alone beat an old gentleman, but he must say that these entrepreneurs in the United States are not good now, and they are still living in the 90s of the last century.

"$193 billion, if you can pay cash, we can sell all of Pfizer's assets!" Yin Ruide decided to show the strong spirit of the Americans, and he could not be completely dominated by the opponent in the negotiations.

He must continue this negotiation, because only if Xu Teng nods and agrees, and uses the connections of Huayin AIG, Pfizer and the Cinton family to lobby the White House, Pfizer can Pfizer escape the hell of the United States.

He just can't talk like that, he doesn't have any leverage at all.

If Xu Teng used a Chinese company to buy Pfizer, first, he would not agree, and second, he could be tsundere, but Xu Teng used AstraZeneca to buy Pfizer, which is difficult to be tsundere.

AstraZeneca's standard return on equity is currently around 30%, much higher than Pfizer, and AstraZeneca accounts for 9 of the 110 patented drugs with annual sales of more than $1 billion in the world, which is basically the same as Pfizer.

Although AstraZeneca's prescription drug sales are half lower than Pfizer's, its profitability and net profit are a cut higher than Pfizer's.

Capital is realistic.

Which company has a higher return on investment and is more profitable, the blind can see it.

And what about the god of capital?

Yin Ruide wanted to embarrass Xu Teng and quote a price of 193 billion US dollars, and he was very sure that this price made Xu Teng speechless, he didn't even add a 20% premium on the basis of market value, and the market value was reported as much as possible!

After all, he has also been doing business for decades, which can not only embarrass Xu Teng, but also not ruin this negotiation, he just wants to force Xu Teng to back down a little.

"Wait a minute!" Xu Teng signaled Yin Ruide not to worry, picked up his mobile phone, dialed President Yuan of China Development Bank and President Yu of the Foreign Exchange Asset Trust Company, and made a three-line phone call to discuss the situation clearly.

"I need $130 billion in long-term bonds with an annual interest rate of 2.5% to subsidize CPI for 10 years, and I will continue to convert bonds into CDS in the market to share the risk, so it is definitely more stable than buying U.S. bonds. Xu Teng is ready to solve the problem with the bonds of the foreign exchange asset trust company and the policy loan of the China Development Bank.

This is definitely a 2A grade bond, with a solid return on investment, and it is easy to find a guarantee in the financial derivatives market.

"Do you really want to buy Pfizer?" Mr. Yu was surprised, if it was a state-owned enterprise to buy Pfizer, there would be no problem with this bond financing, and there would be no problem with the Huayin consortium, because he was not afraid of losing money, making steady profits without losing money, and could also solve many problems in China's pharmaceutical industry.

Mr. Yu's headache is that Xu Teng used AstraZeneca to acquire Pfizer, which is not easy to deal with, and he has been tossing emotionally for a long time, it is actually China that helped Britain acquire the American pharmaceutical giant, what is this?

"The core problem of Pfizer is that their senior management simply doesn't have a long-term sense of responsibility, just the current market capitalization, regardless of the long-term problem, I can solve this problem. After AstraZeneca's acquisition of Pfizer, I will split Wyeth's assets and sell them to Huateng Medical, and spin off the business of various generic drugs to the Federal Pharmaceutical Group, which means that I can get more than 170 generic and generic drugs for the Federal Pharmaceutical Group. "If Xu Teng's level of doing business is at the level of Yin Ruide and Mr. Yu, he doesn't have to mix.

His strategy is to use AstraZeneca to buy Pfizer to bypass the troubles of Chinese acquisition of American high-tech companies, and then split AstraZeneca-Pfizer and sell the part needed in China to Huateng Medical and Federal Pharmaceutical.

Because when Pfizer acquired Wyeth, Huateng Medical had already acquired Wyeth's nutrition, maternal and child health products and R&D centers, and the Huayin AIG consortium also held Pfizer's debt of more than $30 billion.

In this way, Xu Teng only spent about $60 billion to acquire Wyeth, while Pfizer saved at least 1/3 of the price of acquiring Wyeth in 2009.

"Okay, that's basically no problem, you just agree to it first, you talk about it first, I'll report tomorrow, and strive to get this matter done within a month!" Mr. Yu agreed, and he said, does Xu Teng's way of doing business and ideas still worry about a layman of his level?

"Then thank you, I went to the United States this time, mainly to solve the problem of the pharmaceutical industry of the Huayin Consortium, he sent it to the door himself, I didn't solve most of the problems easily, it's a pity, right?" Xu Teng smiled, understated, and chatted with the two leaders for a few more words before hanging up the phone.

This is the advantage of Chinese capitalists, the other party speaks English, you know, you speak Chinese, the other party does not understand anything.

What Xu Teng said to President Yu and President Yuan, Yin Ruide, the chairman of the Pfizer Group, didn't know at all, so he could only sit at Xu Teng's desk all the time, waiting, and he felt more and more bad.

"$193 billion, paid in a month. Xu Teng agreed to Yin Ruide's price, got up and shook hands with Yin Ruide, which can be regarded as a formal deal, "Let the people of AstraZeneca negotiate with you again on the specific merger contract, this money will be paid by me, and you can enjoy the benefits of this big contract in advance." ”

"......?" Yin Ruide was completely shocked.